FrancophonIA/ELRC3.0 huggingface dataset:
English: Alunbrig 180 mg film-coated tablets brigatinib
Maltese: Alunbrig 180 mg pilloli miksija b'rita brigatinib
English: Severe, life-threatening, and fatal pulmonary adverse reactions, including those with features consistent with ILD/pneumonitis, can occur in patients treated with Alunbrig (see section 4.8).
Maltese: Reazzjonijiet avversi pulmonari severi, li jpoġġu l-ħajja fil-periklu u fatali, inkluż dawk b'karatteristiċi konsistenti mal-ILD/pulmonite, jistgħu jseħħu f'pazjenti ttrattati b'Alunbrig (ara sezzjoni 4.8).
English: Alunbrig 90 mg film-coated tablets brigatinib
Maltese: Alunbrig 90 mg pilloli miksija b'rita brigatinib
English: Efficacy results from ALTA analysis are summarised in Table 4. and the Kaplan-Meier (KM) curve for investigator-assessed PFS is shown in Figure 1.
Maltese: Ir-riżultati tal-effikaċja minn analiżi ta' ALTA huma miġbura fil-qosor f'Tabella 4 u l-kurva ta' KaplanMeier (KM) għal PFS evalwat minn investigatur hija murija f'Figura 1.
English: • methotrexate: a medicine to treat severe joint inflammation, cancer and the skin disease psoriasis
Maltese: • methotrexate: mediċina għall-kura ta' infjammazzjoni severa fil-ġogi, kanċer, u l-marda tal ġilda tal-psorijasi.
English: Each film-coated tablet contains 180 mg brigatinib.
Maltese: Kull pillola miksija b'rita fiha 180 mg brigatinib.
English: • slow heartbeat
Maltese: • ħakk tal-ġilda
English: Outer Carton: Alunbrig 180 mg
Maltese: INFORMAZZJONI BIL-BRAILLE Alunbrig 180 mg
English: • Alunbrig should be withheld until recovery to Grade ≤ 1 (≤ 1.5 × ULN) or to baseline, then resumed at same dose.
Maltese: • Alunbrig għandu jitwaqqaf sakemm ikun hemm irkupru għal Grad ≤ 1 (≤ 1.5 × ULN) jew għallinja bażi, imbagħad jitkompla fl-istess doża.
English: Non-cardiac chest pain Pyrexia
Maltese: Uġigħ mhux kardijaku fissider
English: In Study 101, following administration of a single oral dose of brigatinib (30-240 mg) in patients, the median time to peak concentration (Tmax) was 1-4 hours postdose.
Maltese: Fi Studju 101, wara l-għoti ta' doża waħda orali ta' brigatinib (30-240 mg) fil-pazjenti, il-medja tal-ħin biex tintlaħaq il-konċentrazzjoni massima (Tmax) kienet ta' 1-4-il siegħa wara d-doża.
English: Visual disturbance adverse reactions have occurred in patients treated with Alunbrig (see section 4.8).
Maltese: Ir-reazzjonijiet avversi marbuta ma' disturbi tal-vista seħħew f'pazjenti ttrattati b'Alunbrig (ara sezzjoni 4.8).
English: Testicular toxicity was observed in repeat-dose animal studies.
Maltese: Tossiċità testikulari kienet osservata fi studji b'doża ripetuta fuq l-annimali.
English: • Alunbrig should be withheld until recovery to Grade ≤ 1 (≤ 2.5 × ULN) or to baseline, then resumed at the same dose.
Maltese: • Alunbrig għandu jitwaqqaf sakemm ikun hemm irkupru għal Grad ≤ 1 (≤ 2.5 × ULN) jew għallinja bażi, imbagħad jitkompla fl-istess doża.
English: Alunbrig 30 mg film-coated tablets
Maltese: Alunbrig 30 mg pilloli miksija b'rita
English: Each 90 mg film-coated tablet contains 90 mg brigatinib.
Maltese: Kull 90 mg pillola miksija b'rita fiha 90 mg brigatinib.
English: Round wide mouth high density polyethylene (HDPE) bottles with two-piece polypropylene child resistant screw cap closures with foil induction seal liner, containing either 60 or 120 film-coated tablets, together with one HDPE canister containing a molecular sieve desiccant.
Maltese: Fliexken tondi b'ħalq wiesgħa tal-Polyethylene ta' densità għolja (HDPE, High density polythylene) b'żewġ għotjien tal-polypropylene bil-kamini li ma jistgħux jinfetħu mit-tfal mgħammra b'għeluq tattip foil b'siġill għall-induzzjoni, li fihom 60 jew 120 pillola miksija b'rita, flimkien ma' canister talHDPE li fih dessikant molekulari sieve.
English: The most common sites of extra-thoracic metastasis included 69% brain (of whom 62% had received prior radiation to the brain), 39% bone, and 26% liver.
Maltese: L-iktar siti komuni ta' metastasi ekstratoraċiċi kienu jinkludu 69% moħħ (minn liema 62% kienu rċivew radjazzjoni minn qabel fuq il-moħħ), 39% għadam, u 26% fwied.
English: Each film-coated tablet contains 90 mg brigatinib.
Maltese: Kull pillola miksija b'rita fiha 90 mg brigatinib.
English: • If Grade 3 elevation of CPK recurs, Alunbrig should be withheld until recovery to Grade ≤ 1 (≤ 2.5 × ULN) or to baseline, then resumed at the next lower dose level per Table 1.
Maltese: • Jekk terġa' sseħħ elevazzjoni ta' Grad 3 ta' CPK, Alunbrig għandu jitwaqqaf sakemm ikun hemm irkupru għal Grad ≤ 1 (≤ 2.5 × ULN) jew għallinja bażi, imbagħad jitkompla fil-livell tad-doża aktar baxx li jmiss skont Tabella 1.
English: Alunbrig 90 mg, 180 mg
Maltese: INFORMAZZJONI BIL-BRAILLE Alunbrig 90 mg, 180 mg
English: • skin itching
Maltese: • ħalq xott
English: Grapefruit or grapefruit juice may also increase plasma concentrations of brigatinib and should be avoided (see section 4.2).
Maltese: Il-grejpfrut jew il-meraq tal-grejpfrut jistgħu wkoll iżidu l-konċentrazzjonijiet fil-plażma ta' brigatinib u għandhom ikunu evitati (ara sezzjoni 4.2).
English: • The film-coated tablets are approximately 7 mm in diameter with “U3” on one side and plain on the other side.
Maltese: • Il-pilloli miksija b'rita għandhom dijametru ta' madwar 7 mm, huma mnaqqxa b'“U3” fuq naħa waħda, u xejn fuq in-naħa l-oħra.
English: Abbreviations: ITT = Intent-to-treat
Maltese: Figura 1: Sopravivenza
English: Table 4: Efficacy results in ALTA (ITT population) Efficacy parameter
Maltese: Tabella 4: Riżultati tal-effikaċja f'ALTA
English: In ALTA, elevations of CPK were reported in 50% of patients treated with Alunbrig at the 180 mg regimen.
Maltese: F'ALTA, l-elevazzjonijiet ta' CPK kienu rrappurtati f'50% tal-pazjenti ttrattati b'Alunbrig fuq il-kors ta' 180 mg.
English: The median time to onset for CPK elevations was 27 days.
Maltese: Iż-żmien medjan għallbidu tal-elevazzjonijiet ta' CPK kien ta' 27 jum.
English: Diarrhoeaj
Maltese: Artralġja
English: Film-coated tablets 30 film-coated tablets
Maltese: Komuni ħafna Żieda fil-kreatinina tad-demm
English: How to take Alunbrig
Maltese: X'fih Alunbrig
English: Alunbrig 180 mg film-coated tablets
Maltese: Alunbrig 180 mg pilloli miksija b'rita
English: Very common Hyperglycaemia Hyperinsulinaemiab Hypophosphataemia Decreased appetite Hypokalaemia
Maltese: Ipofosfatemija Tnaqqis fl-aptit Ipokalemija Ipomanjesemija Iponatremija Iperkalċemija
English: Grade 4 elevation of lipase or amylase (> 5.0 x ULN)
Maltese: Elevazzjoni ta' grad 4 ta' lipażi jew amilażi (> 5.0 × ULN)
English: Round wide mouth high density polyethylene (HDPE) bottles with two-piece polypropylene child resistant screw cap with foil induction seal liner closures, containing 30 film-coated tablets, together with one HDPE canister containing a molecular sieve desiccant.
Maltese: Flixkien tondi b'ħalq wiesgħa tal-Polyethylene ta' densità għolja (HDPE, High density polythylene) b'żewġ għotjien tal-polypropylene bil-kamini li ma jistgħux jinfetħu mit-tfal mgħammra b'għeluq tattip fojl b'siġill għall-induzzjoni, li fihom 30 pillola miksija b'rita, flimkien ma' canister tal-HDPE li fih dessikant molekulari sieve.
English: In patients given brigatinib 180 mg once daily, the geometric mean apparent oral clearance (CL/F) of brigatinib at steady state was 13 L/h and the median plasma elimination half-life was 24 h.
Maltese: F'pazjenti li jingħataw brigatinib f'doża ta' 180 mg darba kuljum, il-medja ġeometrika tat-tneħħija orali apparenti (CL/F) ta' brigatinib fi stat fiss kienet ta' 13 L/siegħa u il-medjan tal-half-life taleliminazzjoni fil-plażma kienet ta' 24 siegħa.
English: Escherichia coli bacteria form part of the normal gut flora.
Maltese: Il-batterja Escherichia coli jiffurmaw parti mill-flora normali talmusrana.
English: • The safety profile of Symbioflor 2 is acceptable.
Maltese: • Il-profil tas-sigurtà ta' Symbioflor 2 huwa aċċettabbli.
English: The CHMP opinion was forwarded to the European Commission, which issued a final legally binding decision applicable in all EU Member States on 28/08/2017.
Maltese: L-opinjoni tas-CHMP tressqet quddiem il-Kummissjoni Ewropea, li ħarġet deċiżjoni legalment vinkolanti applikabbli fl-Istati Membri kollha tal-UE fit-28/08/2017.
English: The review of Symbioflor 2 (and associated names) was initiated on 30 March 2016 at the request of Germany, under Article 31 of Directive 2001/83/EC.
Maltese: Ir-rieżami ta' Symbioflor 2 (u l-ismijiet assoċjati) inbeda fit-30 ta' Marzu 2016 fuq talba tal-Ġermanja, skont l-Artikolu 31 tad-Direttiva 2001/83/KE.
English: A randomised study involving around 300 adults suggested that Symbioflor 2 was effective for treating IBS.
Maltese: Studju randomizzat li involva madwar 300 adult issuġġerixxa li Symbioflor 2 kien effettiv biex jikkura lIBS.
English: • Symbioflor 2 should be used for the treatment of irritable bowel syndrome (IBS) only, and it should no longer be used for treating ‘functional gastrointestinal disorders' or other conditions of the gastrointestinal tract.
Maltese: • Symbioflor 2 għandu jintuża għall-kura tas-sindrome tal-musrana irritabbli (IBS) biss, u m'għandux jibqa' jintuża għall-kura ta' “disturbi gastrointestinali funzjonali” jew għal kundizzjonijiet oħra talapparat gastrointestinali.
English: The data included clinical studies, scientific publications, post-marketing experience, as well as information provided by the company and the views of an expert group formed for evaluating Symbioflor 2.
Maltese: Iddata kienet tinkludi studji kliniċi, pubblikazzjonijiet xjentifiċi, esperjenza ta' wara t-tqegħid fis-suq, kif ukoll informazzjoni pprovduta mill-kumpanija u l-fehmiet ta' grupp ta' esperti ffurmat għall-valutazzjoni ta' Symbioflor 2.
English: On 22 June 2017 a review by European Medicines Agency (EMA) concluded that Symbioflor 2 and associated names can continue to be used for treatment of irritable bowel syndrome (IBS) in adults.
Maltese: Fit-22 ta' Ġunju 2017 rieżami mill-Aġenzija Ewropea għall-Mediċini (EMA) ikkonkluda li Symbioflor 2 u l-ismijiet assoċjati jistgħu jibqgħu jintużaw għall-kura tas-sindrome tal-musrana irritabbli (IBS, irritable bowel syndrome) fl-adulti.
English: • You can continue to take Symbioflor 2 for treating symptoms of irritable bowel syndrome by following the information in the medicine's revised package leaflet.
Maltese: • Int tista' tkompli tieħu Symbioflor 2 biex tikkura sintomi tas-sindrome tal-musrana irritabbli billi ssegwi l-informazzjoni fil-fuljett ta' tagħrif rivedut tal-mediċina.
English: Symbioflor 2, which contains Escherichia coli bacteria, has been described as a probiotic, which means that it encourages the growth of beneficial organisms (‘flora') in the gut.
Maltese: Symbioflor 2, li fih il-batterja Escherichia coli, ġie deskritt bħala probijotiku, li jfisser li dan jinkoraġġixxi t-tkabbir ta' organiżmi ta' benefiċċju (“flora”) fil-musrana.
English: The medicine has been described as probiotic, which means that it encourages the growth of beneficial organisms (‘flora') in the gut.
Maltese: Il-mediċina ġiet deskritta bħala probijotiku, li jfisser li din tinkoraġġixxi t-tkabbir ta' organiżmi ta' benefiċċju (“flora”) fil-musrana.
English: • A study comparing Symbioflor 2 with placebo suggested that it was effective at treating IBS in adults.
Maltese: • Studju li qabbel Symbioflor 2 mal-plaċebo ssuġġerixxa li dan kien effettiv biex jikkura l-IBS fladulti.
English: However, the study had some weaknesses and it did not provide evidence on how well Symbioflor 2 works in different types of IBS.
Maltese: Madankollu, l-istudju kellu xi nuqqasijiet u ma pprovdiex evidenza dwar kemm Symbioflor 2 jaħdem tajjeb f'tipi differenti ta' IBS.
English: Available evidence suggests that the risk of harm from Symbioflor 2 is low.
Maltese: L-evidenza disponibbli tissuġġerixxi li r-riskju ta' ħsara minn Symbioflor 2 huwa baxx.
English: Symbioflor 2 and associated names contains Escherichia coli bacteria some of which have been broken down (autolysed) while others are living.
Maltese: Symbioflor 2 u l-ismijiet assoċjati fih il-batterja Escherichia coli li xi ftit minnhom tkissru (ġew awtolizzati) waqt li oħrajn baqgħu jgħixu.
English: • An observational study involving adolescents and children aged over 4 years did not provide sufficient evidence of efficacy and safety in children and adolescents.
Maltese: • Studju ta' osservazzjoni li involva adolexxenti u tfal li għandhom aktar minn 4 snin ma pprovdiex biżżejjed evidenza dwar l-effikaċja u s-sigurtà fit-tfal u fl-adolexxenti.
English: However, the medicine should no longer be used more widely to treat so-called functional gastrointestinal disorders, a group of disorders with a variety of causes that may require different treatment approaches.
Maltese: Madankollu, il-mediċina m'għandhiex tibqa' tintuża b'mod aktar mifrux biex tikkura dawk imsejħa disturbi gastrointestinali funzjonali, grupp ta' disturbi b'varjetà ta' kawżi li jistgħu jeħtieġu approċċi ta' kura differenti.
English: • The company will need to carry out a well-designed study to demonstrate the efficacy and safety of Symbioflor 2 for treating different variants of IBS, as a condition for continuing to market it.
Maltese: • Il-kumpanija se jkollha tagħmel studju mfassal tajjeb biex turi l-effikaċja u s-sigurtà ta' Symbioflor 2 għall-kura ta' varjanti differenti tal-IBS, bħala kundizzjoni biex tkompli tqiegħdu fis-suq.
English: Medicines containing Escherichia coli are available as oral drops in Austria, Germany and Hungary under the following invented names: Symbioflor 2, Symbioflor E. Coli and Symbioflor Escherichia.
Maltese: Il-kumpanija li tqiegħed Symbioflor 2 fis-suq ma ppreżentatx data biex tappoġġja l-użu tiegħu f'“disturbi gastrointestinali funzjonali” u qablet li tneħħi dan l-użu mill-awtorizzazzjoni tal-mediċina.
English: The review was carried out by the Committee for Medicinal Products for Human Use (CHMP), responsible for questions concerning medicines for human use, which adopted the Agency's opinion.
Maltese: Ir-rieżami sar mill-Kumitat għall-Prodotti Mediċinali għall-Użu mill-Bniedem (CHMP), responsabbli għal mistoqsijiet dwar mediċini għall-użu mill-bniedem, li adotta l-opinjoni tal-Aġenzija.
English: • Speak with a pharmacist or your doctor if your symptoms of irritable bowel syndrome do not improve with Symbioflor 2 or if they get worse.
Maltese: • L-informazzjoni dwar il-prodott se tiġi aġġornata f'konformità ma' dan ir-rieżami ta' Symbioflor 2.
English: Since the available data were not sufficiently robust for the CHMP to draw conclusions on how well Symbioflor 2 works and whether it is effective for any particular type of IBS, the CHMP has asked the company to carry out a well-designed study on effectiveness and safety among patients with different features of IBS (e.g. those with diarrhoea or with constipation as an important feature).
Maltese: Peress li d-data disponibbli ma kinitx robusta biżżejjed sabiex is-CHMP ikun jista' jagħmel konklużjonijiet dwar kemm jaħdem tajjeb Symbioflor 2 u jekk huwiex effettiv għal kwalunkwe tip ta' IBS, is-CHMP talab lill-kumpanija biex tagħmel studju imfassal tajjeb dwar l-effettività u s-sigurtà f'pazjenti b'karatteristiċi differenti tal-IBS (eż. dawk bid-dijarea jew bl-istitikezza bħala karatteristika importanti).
English: It is marketed in some European Union countries for treating irritable bowel syndrome, functional gastrointestinal diseases and some other gastrointestinal disorders and for regulating the immune system.
Maltese: Dan jitqiegħed fis-suq f'xi pajjiżi tal-Unjoni Ewropea biex jikkura s-sindrome tal-musrana irritabbli, mard gastrointestinali funzjonali u xi disturbi gastrointestinali oħra u biex jirregola s-sistema immuni.
English: The CHMP recommendation was sent to the European Commission which issued a legally binding decision valid throughout the EU.
Maltese: Ir-rakkomandazzjoni tas-CHMP intbagħtet lill-Kummissjoni Ewropea li ħarġet deċiżjoni legalment vinkolanti valida madwar l-UE kollha.
English: You should not use Symbioflor 2 for conditions affecting the gut other than irritable bowel syndrome.
Maltese: M'għandekx tuża Symbioflor 2 għal kundizzjonijiet li jaffetwaw il-musrana minbarra s-sindrome tal-musrana irritabbli.
English: The full EPAR for Clopidogrel ratiopharm GmbH can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: L-EPAR sħiħ għal Clopidogrel ratiopharm GmbH jinstab fis-sit elettroniku tal-Aġenzija: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Clopidogrel ratiopharm GmbH is a ‘generic medicine'.
Maltese: Clopidogrel ratiopharm GmbH huwa ‘mediċina ġenerika'.
English: The European Commission granted a marketing authorisation valid throughout the EU for Clopidogrel ratiopharm GmbH on 28 July 2009.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-UE kollha għal Clopidogrel ratiopharm GmbH fit-28 ta' Lulju 2009.
English: This is then followed by the standard 75 mg dose once a day for at least four weeks (in ST segment elevation myocardial infarction) or for up to 12 months (in non-ST segment elevation syndrome).
Maltese: Dan hu segwit minn doża standard ta' 75 mg darba kuljum għal tal-inqas erba' ġimgħat (f'infart mijokardijaku ta' elevazzjoni tas-segment ST) jew għal mhux iktar minn 12-il xahar (fil-preżenza ta' sindromu mingħajr elevazzjoni tas-segment ST).
English: Clopidogrel ratiopharm GmbH is used in adults to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries).
Maltese: Clopidogrel ratiopharm GmbH jintuża f'adulti biex jipprevjeni każijiet aterotrombotiċi (problemi li jirriżultaw minn demm magħqud u t-twebbis tal-arterji).
English: Clopidogrel ratiopharm GmbH is a medicine that contains the active substance clopidogrel.
Maltese: Clopidogrel ratiopharm GmbH huwa mediċina li fiha s-sustanza attiva klopidogrel.
English: The standard dose of Clopidogrel ratiopharm GmbH is one 75 mg tablet once a day.
Maltese: Id-doża rakkomandata ta' Clopidogrel ratiopharm GmbH hija pillola waħda ta' 75-mg kuljum.
English: This means that Clopidogrel ratiopharm GmbH is similar to a ‘reference medicine' already authorised in the European Union (EU) called Plavix.
Maltese: Dan ifisser li Clopidogrel ratiopharm GmbH huwa simili għall-‘mediċina ta' referenza' diġà awtorizzata fl-Unjoni Ewropea (UE) bl-isem Plavix.
English: In acute coronary syndrome, Clopidogrel ratiopharm GmbH is used together with aspirin and treatment generally starts with a loading dose of four 75 mg tablets.
Maltese: Fissindromu koronarju akut, Clopidogrel ratiopharm GmbH jintuża mal-aspirina u t-trattament ġeneralment jibda b'doża ta' tagħbija (loading dose) ta' erba' pilloli ta' 75 mg.
English: Because Clopidogrel ratiopharm GmbH is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as the reference medicine's.
Maltese: Peress li Clopidogrel ratiopharm GmbH huwa mediċina ġenerika u huwa bijoekwivalenti għall-mediċina ta' referenza, tqies li l-benefiċċji u r-riskji huma l-istess bħal mediċini ta' referenza.
English: Clopidogrel ratiopharm
Maltese: Is-sustanza attiva f'Clopidogrel ratiopharm
English: Because Clopidogrel ratiopharm GmbH is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Plavix.
Maltese: Billi Clopidogrel ratiopharm GmbH huwa mediċina ġenerika, l-istudji fil-pazjenti ġew limitati għal testitjiet biex jiddeterminaw il-bijoekwivalenza tiegħu mal-mediċina ta' referenza, Plavix.
English: This is a summary of the European public assessment report (EPAR) for Clopidogrel ratiopharm GmbH.
Maltese: Dan huwa sommarju tar-Rappport Pubbliku Ewropew ta' Valutazzjoni (EPAR) għal Clopidogrel ratiopharm GmbH.
English: The Committee recommended that Clopidogrel ratiopharm GmbH be given marketing authorisation.
Maltese: Il-Kumitat irrakkomanda li Clopidogrel ratiopharm GmbH jingħata awtorizzazzjoni għat-tqegħid fis-suq.
English: Clopidogrel ratiopharm GmbH can be given to the following groups of patients:
Maltese: Clopidogrel ratiopharm GmbH jista' jingħata lill-gruppi ta' pazjenti li ġejjin:
English: What are the benefits and risks of Clopidogrel ratiopharm GmbH?
Maltese: X'inhuma l-benefiċċji u r-riskji ta' Clopidogrel ratiopharm GmbH ?
English: What is Clopidogrel ratiopharm GmbH?
Maltese: X'inhu Clopidogrel ratiopharm GmbH?
English: Other information about Clopidogrel ratiopharm GmbH
Maltese: Informazzjoni oħra dwar Clopidogrel ratiopharm GmbH
English: • patients who have a condition known as ‘acute coronary syndrome', when it should be given with aspirin (another medicine that prevents blood clots), including patients who have had a stent inserted (a short tube placed in an artery to prevent it closing up).
Maltese: • pazjenti b'kundizzjoni magħrufa bħala ‘sindromu koronarju akut', meta għandu jingħata malaspirina (mediċina oħra li tipprevjeni l-formazzjoni ta' emboli tad-demm), inkluż f'pazjenti li tkun iddaħħlitilhom stent (tubu qasir imqiegħed f'arterja biex ma jħallihiex tingħalaq). Clopidogrel ratiopharm GmbH jista' jintuża f'pazjenti li jkollhom infart mijokardijaku flimkien ma' ‘elevazzjoni fis-segment ST' (riżultat anomalu tal-elettrokardjogramma jew ECG) meta t-tabib ikun ikkunsidra li jkunu se jibbenefikaw mit-trattament.
English: The active substance in Clopidogrel ratiopharm GmbH, clopidogrel, is an inhibitor of platelet aggregation.
Maltese: GmbH ,klopidogrel, hi inibitur tal-aggregazzjoni tal-pjastrini (platelets).
English: Why has Clopidogrel ratiopharm GmbH been approved?
Maltese: Għaliex ġie approvat Clopidogrel ratiopharm GmbH?
English: ATCvet code: QJ01XQ02.
Maltese: QJ01XQ02.
English: and Escherichia coli.
Maltese: u Escherichia coli.
English: Indication Dosage (active substance)
Maltese: Indikazzjoni Dożaġġ (sustanza attiva)
English: 26, Rue de la Chapelle 68330 Huningue
Maltese: Elanco France S.A.S. 26, Rue de la Chapelle 68330 Huningue Franza
English: Responsible use of antimicrobials:
Maltese: Użu responsabbli ta' antimikrobijali:
English: Plastic scoops: 50% HIPS (High Impact Polystyrene) and 50% GPPS (General Purpose Polystyrene).
Maltese: Imgħaref tal-plastik: 50% HIPS (High Impact Polystyrene - Polystyrene ta' Impatt Qawwi) u 50% GPPS (General Purpose Polystyrene - Polystyrene ta' Għan Ġenerali).
English: The active substance in Econor, valnemulin, is an allowed substance as described in table 1 of the annex to Commission Regulation (EU) No 37/2010:
Maltese: Is-sustanza attiva f'Econor, valnemulin, hija sustanza ammissibbli kif deskritt fit-tabella 1 fl-anness tar-Regolament tal-Kummissjoni (UE) Nru 37/2010:
English: Species
Maltese: Specijiet
English: In a field trial, treated rabbits showed a lower frequency of impaction and diarrhoea than untreated rabbits (4% and 12% vs 9% and 13% respectively).
Maltese: Fi prova prattika, il-fniek ikkurati wrew frekwenza iktar baxxa ta' impazzjoni u dijarrea minn fniek mhux ikkurati (4% u 12% vs 9% u 13% rispettivament).
English: 73% - 95% of the daily dose of total radioactivity was recovered from the faeces.
Maltese: 73% - 95% tad-doża ta' kuljum tarradjuattività totali ġew irkuprati mill-ippurgar.
English: Responsible use of antimicrobials
Maltese: Użu responsabbli ta' antimikrobijali
English: Date of last renewal: 06/03/2009.
Maltese: Data tal-ewwel awtorizzazzjoni: 12/03/1999 Data tal-aħħar tiġdid: 06/03/2009.
English: Active substance Valnemulin hydrochloride
Maltese: Sustanza attiva Valnemulin hydrochloride
English: Econor 50% premix Sandoz GmbH Biochemiestrasse 10 6250 Kundl AUSTRIA
Maltese: Sandoz GmbH Biochemiestrasse 10 6250
English: Valnemulin has little activity against Enterobacteriaceae, such as Salmonella spp.
Maltese: Valnemulin ftit li xejn huwa attiv kontra Enterobacteriaceae, bħal Salmonella spp.
English: 100 µg/kg 500 µg/kg 50 µg/kg
Maltese: Valnemulin1 Valnemulin Majjali, fniek 100 µg/kg 500 µg/kg
English: Pharmacologically active substance
Maltese: Sustanza farmakoloġi kament attiva
English: Kidney Liver Muscle
Maltese: Kliewi Fwied Muskoli
English: METHOD AND ROUTE(S) OF ADMINISTRATION In-feed use.
Maltese: METODU U MOD(I) TA' AMMINISTRAZZJONI